Epigenomics
Epigenomics is a monthly epigenomics journal published by Future Medicine. Launched in 2009, it carries a 2025 impact factor of 3.1.Epigenomics是 Future Medicine 出版的表观基因组学月刊，2009 年创刊，2025 年影响因子为 3.1。[1]
Scope
- Scope: the journal covers all aspects of research on epigenomics and epigenetics and their implications for diagnosis, prognosis and therapeutics.学科定位： 期刊覆盖表观基因组学与表观遗传学研究的各个方面，及其对诊断、预后与治疗的启示。
- Editorial orientation: the journal follows key technological advances that elucidate the inner working of the genome and explores how they bear on our understanding of human health and disease.办刊取向： 期刊以技术进展为线索，报道解析基因组内在运作方式的关键突破及其对人类健康问题的影响。
- Founding positioning: the launch announcement framed the title as a critical overview of the latest and most significant advances as they unfold.创刊定位： 创刊公告将刊物定位为对最新最重要进展的批判性综述平台，兼具快报与深度评述。
- Publishing model: the journal is subscription-based with an open access option available.出版模式： 期刊为订阅型刊物，支持开放获取发表选项。
- Indexing and metrics: indexed in the Science Citation Index Expanded, Medline, Scopus, EMBASE and BIOSIS among others, the journal sits in the second quartile of genetics and heredity, with a 2025 impact factor of 3.1.收录与指标： 被科学引文索引扩展版、Medline、Scopus、EMBASE 与 BIOSIS 等数据库收录，在遗传学类别中列第二区，2025 年影响因子为 3.1。[2]
History
- Founded in 2009: the journal was launched by Future Medicine, part of the Future Science Group, in 2009, beginning as a bimonthly and later turning monthly.2009年创刊： 期刊于 2009 年由 Future Science Group 旗下的 Future Medicine 创刊，创刊时为双月刊，后改为月刊。
- Launch announcement: the launch news set out an editorial office led by two senior editors, supported by three associate editors and an advisory panel of more than thirty international experts.创刊公告： 创刊新闻列明编辑部由两位资深编辑主持，配三位副编辑与三十余位国际专家顾问。[3]
- Recent metrics: the impact factor stood at 4.112 in 2019, 3.8 in 2022 and 3.1 in 2025.近年指标： 影响因子 2019 年为 4.112，2022 年为 3.8，2025 年为 3.1。
- Frequency: the journal appears monthly with twelve issues a year.刊期： 期刊为月刊，每年出版 12 期。
Editors
- Editors-in-chief: the journal is led by two editors-in-chief, James G. Herman and Jörg Tost.现任主编： 期刊设双主编，分别为 James G. Herman 与 Jörg Tost。
- Editorial background: Herman works on cancer epigenetics, based at the Johns Hopkins Oncology Center at launch and later listed with the University of Pittsburgh Cancer Institute, while Tost is at the Centre National de Génotypage in France.主编背景： Herman 是肿瘤表观遗传学方向的学者，创刊时任职于约翰霍普金斯肿瘤中心，后列名匹兹堡大学癌症研究所；Tost 任职于法国国家基因组测序中心。
- Editorial board: the board is organised along technological directions, covering DNA methylation, histone modification and chromatin analysis among the core methods of epigenomics.编委构成： 编委会按技术方向组织，覆盖 DNA 甲基化、组蛋白修饰与染色质分析等表观基因组学核心方法。[4]
- Submission and peer review: manuscripts are lodged through an online system and undergo peer review.投稿与评审： 稿件经在线系统递交，接受同行评审。
- Editorial policy: the journal stresses the clinical translation of epigenomic technologies, favouring results that connect to diagnosis, prognosis and therapeutics.编辑方针： 期刊强调表观基因组学技术的临床转化价值，偏好与诊断、预后和治疗相衔接的成果。